Assessment of selected haemostatic parameters in obese patients;Ocena wybranych parametrów układu hemostazy u osób otyłych

Endokrynologia Polska

Volumn 58, Issue 6, 2007, Pages 505-509

  Świa̧tkowska Stodulska, Renata ^a   Skibowska Bieliñska, Anna ^b   Ba̧kowska, Alicja ^a   Wiśniewski, Piotr ^a   Sworczak, Krzysztof ^a  

^a MEDICAL UNIVERSITY OF GDANSK   (Poland)

^b AM   (Poland)

Author keywords

Disturbances of haemostasis; Fibrynolysis; Obesity

Indexed keywords

ANTIPLASMIN; FIBRIN; PROTEIN C; THROMBOMODULIN;

ADULT; ARTICLE; BLOOD; BODY MASS; CASE CONTROL STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HEMOSTASIS; HUMAN; MALE; MIDDLE AGED; OBESITY; THROMBOEMBOLISM;

ADULT; ANTIPLASMIN; BODY MASS INDEX; CASE-CONTROL STUDIES; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FIBRIN; HEMOSTASIS; HUMANS; MALE; MIDDLE AGED; OBESITY; PROTEIN C; THROMBOEMBOLISM; THROMBOMODULIN;

EID: 43549121078     PISSN: 0423104X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (31)

1. Swiatkowska-Stodulska R, Kazimierska E, Sworczak K, Czestochowska E. Zaburzenia hemostazy u osób otyłych. Wiad Lek 2007; 60: 185-188.
2. Alessi MC, Bastelica D, Morange P i wsp. Plasminogen activator inhibitor 1, transforming growth factor-beta 1 and BMI are closely associated in human adipose tissue during morbid obesity. Diabetes 2000; 49: 1374-1380. (Pubitemid 30624239)
3. Avellone G, Di Garbo V, Cordova R, Raneli G, De Simone R, Bompiani G. Coagulation, fibrynolysis and haemorheology in premenopausal obese women with different body fat distribution. Thromb Res 1994; 75: 223-231. (Pubitemid 24241954)
4. Balleisen L, Bailey J, Epping PH, Schulte H, van de Loo BJ. Epidemiological study on factor VII, factor VIII, and fibrino-gen in an industrial population: I. Baseline data on the relation to age, gender, body-weight, smoking, alcohol, pill-using, and menopause. Thromb Haemost 1985; 54: 475-479. (Pubitemid 16255676)
5. Bastard JP, Pieroni L. Plasma plasminogen activator inhibitor 1, insulin resistance and android obesity. Biomed Pharmaco-ther 1999; 53: 455-461. (Pubitemid 30019381)
6. Cigolini M, Targher G, Bergamo IA, Tonoli M, Agostino G, De Sandre G. Visceral fat accumulation and its relation to plasma hemostatic factors in healthy men. Arterioscler, Thromb and Vasc Biol 1996; 16: 368-374. (Pubitemid 26084311)
7. Conlan MG, Folsom AR, Finch A, Davis CE, Sorlie P, Marcucci G, Wu KK. Associations of factor VIII and von Willebrand factor with age, race, sex, and risk factors for atherosclerosis. The Atherosclerosis Risk in Communities (ARIC) Study. Thromb Ha-emost 1993; 70: 380-385. (Pubitemid 23254660)
8. De Pergola G., Pannacciulli N. Coagulation and fibrynolysis abnormalities in obesity. J Endocrinol Invest 2002; 25: 899-904.
9. Folsom AR, Qamhieh HT, Wing RR i wsp. Impact of weight loss on plasminogen activator inhibitor (PAI-1), factor VII, and other hemostatic factors in moderately overweight adults. Ar-terioscler Thromb 1993; 13: 162-169. (Pubitemid 23056789)
10. Mertens I, Van Gaal LF. Obesity, haemostasis and the fibryno-lytic system. Obes Rev 2002; 3: 85-101.
11. Mutch NJ, Wilson HM, Booth NA. Plasminogen activator inhibi-tor-1 and haemostasis in obesity. Proc Nutr Soc 2001; 60: 341-347. (Pubitemid 32772449)
12. Rosito GA, D'Agostino RB, Massaro J i wsp. Association between obesity and a prothrombotic state: The Framingham Offspring Study. Thromb Haemost 2004; 91: 683-689. (Pubitemid 38477447)
13. Hori Y, Gabazza EC, Yano Y, Katsuki A, Suzuki K, Adachi Y, Sumida Y. Insulin resistance is associated with increased circulating level of thrombin-activatable fibrinolysis inhibitor in type 2 diabetic patients. J Clin Endocrinol Metab 2002; 87: 660-665. (Pubitemid 34158234)
14. Kohler HP. Insulin resistance syndrome: interaction with coagulation and fibrinolysis. Swiss Med Wkly 2002; 132: 241-252.
15. Anand SS, Yi Q, Gerstein H i wsp. Relationship of metabolic syndrome and fibrynolytic dysfunction to cardiovascular disease. Circulation 2003; 108: 420-425. (Pubitemid 36935534)
16. Cierniewski CS. Postepy wiedzy o regulacji fibrynolizy. Acta Haematol Pol 1994; (supl. 2): 15-26.
17. Kopec M. Róznorodne i zmienne funkcje trombiny. Acta Ha-ematol Pol 1997; 28: 95-100.
18. Kopec M. Postepy w poznawaniu mechanizmów aktywacji krzepniecia krwi. Acta Haematol Pol 1994; 25 (supl. 2): 5-13.
19. Esmont CT. The regulation of natural anticoagulant pathways. Science 1987; 235: 1348-1352.
20. Łopaciuk S. Zakrzepy i zatory. PZWL, Warszawa 2000.
21. Rosenberg RD. The heparin-antithrombin system: a natural anticoagulant mechanism. W: Colman RW, Hirsh J, Marder VJ, Salzman EW (red.). Hemostasis and Thrombosis. Basic principles and clinical practice. Lippincott. Philadelphia 1987; 1373-1392.
22. Wencel K. Naturalne czynniki hamujace krzepniecie krwi (an-tytrombina III, białka C i S). Pol Tyg Lek 1992; 47: 377-380.
23. Batist G, Bothe A Jr, Bern M, Bistrian BR, Blackburn GL. Low antithrombin III in morbid obesity: return to normal with weight reduction. J Parenter Enteral Nutr 1983; 7: 447-449. (Pubitemid 13002366)
24. De Pergola G, De Mitrio V, Sciaraffia M i wsp. Lower androge-nicity is associated with higher plasma levels of prothrombotic factors irrespective of age, obesity, body fat distribution, and related metabolic parameters in men. Metabolism 1997; 46: 1287-1293. (Pubitemid 27473512)
25. De Pergola G, De Mitrio V, Giorgino F i wsp. Increase in both pro-thrombotic and anti-thrombotic factors in obese premeno-pausal women: relationship with body fat distribution. Int J Obes Metab Disord 1997; 21: 527-535. (Pubitemid 27273497)
26. Bowles LK, Cooper JA, Howarth DJ, Miller GJ, MacCallum PK. Associations of haemostatic variables with body mass index: a community-based study. Blood Coagul Fibrinolysis 2003; 14: 569-573. (Pubitemid 37083173)
27. Urban M, Wojtkielewicz K, Głowinska B, Peczynska J. Soluble thrombomodulin-a molecular marker of endothelial cell injury in children and adolescents with obesity. Endokrynol Diabetol Chor Przemiany Materii Wieku Rozw 2005; 11: 73-77. (Pubitemid 40904509)
28. Rosc D, Drewniak W, Kinasz-Rózycka I, Kulwas A, Michalski A. Thrombomodulin, von Willebrand factor and tissue plasmi-nogen activator in the blood plasma of obese women and men. Pol Merkuriusz Lek 2003; 15: 518-520. (Pubitemid 38120678)
29. Vazquez LA, Pazos F, Berrazueta JR i wsp. Effects of changes in body weight and insulin resistance on inflammation and endothelial function in morbid obesity after bariatric surgery. J Clin Endocrinol Metab 2005; 90: 316-322. (Pubitemid 40116674)
30. Bjorntorp P. Endocrine abnormalities in obesity. Diabetes Rev 1997; 5: 52-68. (Pubitemid 27198913)
31. Primrose JN, Davies JA, Prentice CR, Hughes R, Johnston D. Reduction in factor VII, fibrinogen and plasminogen activator inhibitor-1 activity after surgical treatment of morbid obesity. Thromb Haemost 1992; 68: 396-399.